The Trauma Market experienced another quarter of healthy growth as the WW and US Trauma Markets ended Q221 up YoY compared to Q220. Looking forward to Q321, SmartTRAK feels that trauma procedures will likely not be as heavily impacted by the rise in the Delta variant as its elective procedure counterparts. We will continue to monitor the situation as the variant impacts states, as recently observed in Texas.
Among the many topics covered in detail in our comprehensive Q221 Trauma Market Recap* are:
- Complete Q221 Trauma Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Trauma Market News including Revenues, Data, Charts and Shares
- IM Nails Are Back on Top
- New Developments in Plates & Screws
- Q221 IM Nailing & Plates and Screws Patents
- Regulatory Highlights
Historically one of the largest Trauma segments, Q221 saw IM Nails touted as a driving force for major trauma players. US IM Nail market leader, Stryker (45.8% Q2 US share), commented that while its US business benefited from COVID-19 recovery as well as the ongoing execution of the Wright US sales integration, its US Trauma & Extremities business experienced ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has recently launched five new modules for 2021, including Arthroscopic Technologies, Pediatric Extremities, Pediatric Spine and Pediatric Trauma. Click here to see details of the exciting new content now available on SmartTRAK.